Open AccessNew clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
Author(s) -
N. A. Dragomiretskaya,
А. И. Тарзиманова,
Yulia A. Kucherova,
В. И. Подзолков
Publication year - 2021
Publication title -
terapevtičeskij arhiv
Language(s) - English
Resource type - Journals
eISSN - 2309-5342
pISSN - 0040-3660
DOI - 10.26442/00403660.2021.09.201016
Subject(s) - medicine , spironolactone , mineralocorticoid receptor , hyperaldosteronism , refractory (planetary science) , mineralocorticoid , eplerenone , heart failure , aldosterone , pharmacology , endocrinology , intensive care medicine , cardiology , physics , astrobiology
Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to new information about its antifibrotic and antiproliferative effects, both cardiac and extracardiac. The article also discusses the possibility of using spironolactone in patients with the new coronavirus infection SARS-CoV-2 (COVID-19).